Pegmolesatide Treatment for Anemia in Patients Undergoing Long-term Dialysis

This study is testing pegmolesatide, a new monthly injection drug for anemia (low red blood cell count) in people on long-term dialysis who are currently on older anemia medications (called ESAs, like erythropoietin). The goal is to see if this drug can better control anemia with less frequent dosing. **You may be eligible if...** - You are between 18 and 80 years old on hemodialysis or peritoneal dialysis for at least 3 months - You are currently taking ESA injections for anemia with suboptimal response - Your hemoglobin (blood count) is in a specific low-to-moderate range - You have adequate iron stores **You may NOT be eligible if...** - You have active cancer, a blood disorder, or other cause of anemia (like bleeding) - You had a stroke, heart attack, blood clot, or pulmonary embolism in the past 6 months - You received blood transfusions or anabolic steroids recently - You are pregnant or planning to become pregnant - You have very high, uncontrolled blood pressure Talk to your doctor to see if this trial is right for you.